InvestorsHub Logo

ralphey

03/04/21 1:23 PM

#328043 RE: BobWayne #328041

Yes BOb I must admit I never saw it going this low after CHMP positive outlook on med - I thought $7.50 would be limit but it will come back

sstyles

03/04/21 1:41 PM

#328046 RE: BobWayne #328041

I commented a few weeks ago market risk was a concern for us....

others told me interest rates are low....the market will not correct. LOL

oh well this is AMRN. now we have market correction to perhaps deal with.

Retired2019

03/04/21 1:51 PM

#328048 RE: BobWayne #328041

Down 40% in a month after successful EMA CHMP opinion approval and record Q4 and YOY earnings release. Very Frustrating. I'm not buying Thero said "GIA in the EU" so everyone jumped ship. Until, unless Amarin has any substantial offer worth considering to partner with someone or sell the EU Vazkepa franchise rights, GIA is the only strategy. They can't do nothing, they have to advocate and begin implementing a GIA strategy until the status quo changes. With EMA EC decision imminent (approx. 4 wks), 10 year patent exclusivity, P-CVR label indication, and other trial outcomes data in-progress, maybe the status quo is about to change for shareholders.